To earn CME related to this news article, click here. February 19, 2009 — The US Food and Drug Administration (FDA) has approved dexlansoprazole for the healing and maintenance healing of erosive ...
Active ingredient: Dexlansoprazole 30 mg, 60 mg; delayed-release caps. Indications: Treatment of erosive esophagitis (EE) and heartburn related to nonerosive gastroesophageal reflux disease (GERD).
DEERFIELD, IL, USA I January 27, 2016 I Takeda Pharmaceuticals U.S.A., Inc., (Takeda) (TSE: 4502) today announced that the United States (U.S.) Food and Drug Administration (FDA) approved Dexilant ...
March 4, 2010 — The brand name of the heartburn drug dexlansoprazole (Kapidex, Takeda Pharmaceuticals North America Inc) has been changed to Dexilant, the US Food and Drug Administration (FDA) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback